Ulixacaltamide - Praxis Precision Medicine
Alternative Names: PRAX-944; Z 944Latest Information Update: 09 Dec 2025
At a glance
- Originator Zalicus
- Developer Praxis Precision Medicines; Taro Pharmaceuticals USA
- Class Analgesics; Antiepileptic drugs; Benzamides; Piperidines; Small molecules
- Mechanism of Action T-type calcium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential tremor
- Phase II Epilepsy
- No development reported Pain
Most Recent Events
- 04 Dec 2025 Praxis Precision Medicines completes its pre-NDA meeting with FDA for Essential tremor
- 05 Nov 2025 Praxis Precision Medicines plans pre-NDA meeting with the FDA in the fourth quarter of 2025
- 05 Nov 2025 Efficacy data from a phase III Essential3 trial for Essential tremor released by Praxis Precision Medicines